Dr. Pan Zheng is a co-founder of OncoImmune and served as its Chief Medical Officer until the company's successful exit. She led OncoImmune’s clinical development, including the first-in-human trials in healthy volunteers and cancer patients, and successfully completed Phase II and Phase III clinical trials, establishing the safety and therapeutic efficacy of OncoImmune’s flagship product.
Prior to serving as the Chief Medical Officer of OncoC4, she held faculty positions at academic institutions, including The Ohio State University, Children’s National Medical Center, and the Institute of Human Virology at the University of Maryland School of Medicine. Dr. Zheng has undergone training in anatomical and clinical pathology and is a board-certified physician by the American Board of Pathology.
